News | October 13, 2025
Cadila launches allergy relief tablet Dlorfast-M
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Merck will showcase results in innovative solutions in HIV treatment and prevention
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Subscribe To Our Newsletter & Stay Updated
